---
title: "Moderna stock soars 15% as bulls cheer drug pipeline update: Next stop $75?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290996249.md"
description: "Moderna shares surged nearly 15% to ~$69 following a positive business update on its drug pipeline, including progress in cancer and autoimmune treatments. The stock has risen ~42% over the past month, outperforming the S&P 500. Technical indicators suggest potential upside toward $75 if resistance at $68 is broken, with support at $63. Despite the rally, analysts maintain a Hold rating."
datetime: "2026-06-26T18:05:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290996249.md)
  - [en](https://longbridge.com/en/news/290996249.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290996249.md)
---

# Moderna stock soars 15% as bulls cheer drug pipeline update: Next stop $75?

Moderna (MRNA) shares surged nearly ~15% on Friday to around ~$69 and are now up almost ~42% over the past month. The stock has also crushed the S&P 500 (SP500)'s return of ~7.49%, delivering gains of more than ~114% over the same period. The Moderna stock rally came after the company shared a major business update on its Science Day event that gav...

### Related Stocks

- [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md)
- [MRNX.US](https://longbridge.com/en/quote/MRNX.US.md)
- [MRNY.US](https://longbridge.com/en/quote/MRNY.US.md)
- [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md)

## Related News & Research

- [Moderna advances in vivo CAR-T candidate mRNA-6007 into early development for autoimmune diseases](https://longbridge.com/en/news/290822266.md)
- [This Stock Has Already Doubled This Year and Is Still Racing Towards a Major Catalyst](https://longbridge.com/en/news/290916339.md)
- [Moderna Maintained at Hold as Analyst Weighs Leading mRNA Platform Against Early-Stage Pipeline Risks](https://longbridge.com/en/news/290970667.md)
- [Moderna spotlights expanding mRNA pipeline at Science Day event](https://longbridge.com/en/news/290819631.md)
- [Hold Rating Reiterated on Moderna as Analyst Keeps $49 Price Target Amid Long-Term Pipeline Potential and Near-Term Execution Risks](https://longbridge.com/en/news/290971983.md)